A 913-person economic evaluation of the PReDicT antidepressant algorithm found nearly identical EQ-5D quality-of-life gains vs. treatment as usual (+0.139 vs. +0.140) and nearly identical societal cost reductions (−€2,589 vs. −€2,602), while cost-effectiveness probabilities were only 46% to 59% at trial level but exceeded 80% in the UK.1 The algorithm signal was country-specific and capability-weighted, …
Adding music to ketamine psychotherapy failed to provide extra antidepressant benefit over matched non-music support in a 2026 randomized clinical trial (RCT; a study that assigns participants to groups by chance), even though the full 6-infusion ketamine-psychotherapy course was followed by large depression-score reductions. Research Highlights Music added no confirmed MADRS benefit: in the MUSIK …
Intranasal esketamine — FDA-approved for treatment-resistant depression in 2019 — failed cost-effectiveness benchmarks against four cheaper third-line options in a 2026 Hong Kong modeling study, with incremental cost-effectiveness ratios (ICERs) of US$134,127 to US$312,750 per quality-adjusted life-year (QALY) at a US$50,000/QALY willingness-to-pay (WTP) threshold.1 Combination antidepressant therapy was the most cost-effective strategy modeled. Research Highlights …
A 2026 methylome-wide association study by Shen et al. found 48 CpG methylation sites tied to the quadratic CYP2C19 metabolizer-status term in 18,396 Generation Scotland participants, with 19 sites showing non-linear patterns and targeted replication in 1,238 older adults.1 That supports CYP2C19 as real biology beneath SSRI pharmacogenomics, but it does not prove universal antidepressant …
A 2026 two-cohort connectome study found that post-stroke depressive symptoms tracked damage to networks weighted by the serotonin transporter and vesicular acetylcholine transporter: 5-HTT damage predicted depression in Leipzig (OR 2.4, 95% CI 1.15–5.02) and Oxford (OR 2.05, 95% CI 1.03–4.09), while VAChT damage also replicated across both cohorts.1 The dopamine part of the original …
A 2026 retrospective case series of 22 adults with treatment-resistant depression and comorbid PTSD found that trauma re-experiencing during intranasal esketamine disappeared over later sessions in 72.7% of patients, while 27.3% stopped esketamine because the flashbacks persisted.1 Research Highlights Flashbacks usually faded, but not always: In 16 of 22 patients (72.7%), esketamine-related trauma re-experiencing disappeared …
Parenteral clomipramine has a strong clinical myth around it: bypass the gut, raise parent-drug exposure quickly, and maybe accelerate rescue in severe depression or OCD. A 2026 systematic review found the route advantage was not clearly proven: in depression, 5 RCTs without high risk of bias did not show clear IV or IM superiority over …